Research Group
Prostate and Urologic Cancer
Sponsor
University of Illinois at Chicago
Status
Completed
NCT ID
NCT01594502
The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.
Intervention
Dutasteride, Placebo
Condition
Prostate Cancer
Investigators
Peter H Gann, MD, ScD